Fiduciary Group LLC Sells 150 Shares of Eli Lilly and Company (NYSE:LLY)

Fiduciary Group LLC cut its position in Eli Lilly and Company (NYSE:LLY) by 2.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,140 shares of the company’s stock after selling 150 shares during the period. Fiduciary Group LLC’s holdings in Eli Lilly and Company were worth $4,162,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. International Assets Investment Management LLC grew its stake in shares of Eli Lilly and Company by 61,268.8% in the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after acquiring an additional 7,330,815 shares in the last quarter. Sapient Capital LLC purchased a new position in Eli Lilly and Company in the fourth quarter valued at approximately $617,312,000. J.P. Morgan Private Wealth Advisors LLC bought a new position in Eli Lilly and Company during the third quarter valued at $435,736,000. Vanguard Group Inc. grew its holdings in Eli Lilly and Company by 0.9% during the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after purchasing an additional 659,838 shares during the period. Finally, Massachusetts Financial Services Co. MA increased its position in Eli Lilly and Company by 24.2% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,310,859 shares of the company’s stock worth $1,778,362,000 after buying an additional 645,473 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

LLY traded up $8.64 during midday trading on Friday, hitting $733.51. The stock had a trading volume of 2,009,249 shares, compared to its average volume of 2,265,427. Eli Lilly and Company has a 1 year low of $380.77 and a 1 year high of $800.78. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The business has a fifty day moving average of $761.79 and a 200 day moving average of $666.67. The company has a market cap of $696.95 billion, a P/E ratio of 126.47, a price-to-earnings-growth ratio of 1.60 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. During the same quarter in the prior year, the company earned $2.09 EPS. The firm’s revenue was up 28.1% on a year-over-year basis. As a group, equities analysts forecast that Eli Lilly and Company will post 12.51 earnings per share for the current fiscal year.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the subject of several research reports. The Goldman Sachs Group increased their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research note on Thursday, April 11th. BMO Capital Markets upped their price target on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. Citigroup lifted their price target on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Truist Financial restated a “buy” rating and issued a $850.00 price objective on shares of Eli Lilly and Company in a research report on Friday, March 22nd. Finally, DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price on the stock. in a report on Wednesday, February 21st. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $728.05.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.